Wildforce24 Feb 2020 10:49
Not sure if you noticed but quite a bit of this research is outsourced ... https://www.crownbio.com/contact-us
but the main bit ....
CH129-vcE conjugate potently controls tumor growth in vivo, in a COLO205 xenograft
model
Based on the subnamolar in vitro killing potency (65.8 pmol/L EC50) as well as its
intermediate bystander killing activity, we selected CH129-vCE for evaluation of in vivo tumor
control in a COLO205 xenograft model. Tumors were established and dosing started on day
seven. In this model, biweekly administration of four doses of CH129-vcE established a
significant reduction in tumor volume compared to the control ADC, RTX-vcE (two-way
ANOVA, P <0.0001) (Figure 6A). Impressively, 7/10 mice became tumor-free for the duration
of the study. The compounds were well-tolerated, with no adverse effects on mean body
weight (Figure 6B).
what is also interesting something i have never heard off
""" Alternative site-specific conjugation strategies, as well as more potent drugs, for example the very potent Pyrrolobenzodiazepine (PBD), that are currently being evaluated,
would constitute attractive alternatives for conjugation to the 129 mAb (44,45). """"
Pyrrolobenzodiazepines or PBDs, a class of natural products with antibiotic or anti-tumor properties, are produced by various actinomycetes (a broad group of bacteria that form thread-like filaments in the soil and are responsible for the distinctive scent of freshly exposed, moist soil), are sequence selective DNA alkylating compounds. As a class of DNA-crosslinking agents they are significantly more potent than systemic chemotherapeutic drugs. Some PBDs have the ability to recognize and bond to specific sequences of DNA.
You can see why Collaborating with a potential Client is far more important than "just get your cheque book out" because if you know the potential, and can guide research to maximize efficacy ... then that alone achieves a better outcome of monetisation and is far more representative of value because its so more refined and defined ..
One thing is for sure Lindy wants the "best in class" ... moditope is a prime example, with the difficulty of manufacture of hydrophobic peptide conjugate ... Scancell has not given up and switched to alternative adjuvants which any poster on here can research that Scancell already has Data on alternatives
why ?
Efficacy ....
now lets look at Mabs Efficacy ...
Cost of trials are so high ... you put your best foot forward at all times .. because its the trials that Kill you if you don't get all the data in first time around .. we have seen it here with IMM and the placebo effect and MTFB with the liver effect if the data is missing or confused your trial could fail ... result both IMM and MTFB will need fresh trials ... at what cost ?
Time spent now ... in getting it right is paramount, instead of being critical of the delay .. consider the value of monetisation of efficac
Sign In
Follow the stocks
